By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Ortho-McNeil Pharmaceutical, Inc. v. Mylan Pharmaceuticals, Inc. et al.
1:08-cv-00101; filed April 9, 2008 in the Northern District of West Virginia

Infringement of U.S. Patent No. RE39,221 ("Composition Comprising a Tramadol Material and Acetaminophen and Its Use," issued August 1, 2006) following a paragraph IV certification as part of Mylan’s filing of an ANDA to manufacture a generic version of Ortho-McNeil’s Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain).  View the complaint here.

Procter & Gamble Co. v. Teva Pharmaceuticals USA Inc.
1:08-cv-00191; filed April 4, 2008 in the District Court of Delaware

Infringement of U.S. Patent No. 5,583,122 ("Pharmaceutical Compositions Containing Geminal Diphosphonates," issued December 10, 1996) following a paragraph IV certification as part of Teva’s filing of an ANDA to manufacture a generic version of P&G’s Actonel® (risedronate sodium, used to treat and prevent postmenopausal osteoporosis) co-packaged with calcium carbonate tablets.  View the complaint here.

Sanofi-Aventis Deutschland GmbH et al. v. Glenmark Pharmaceuticals Inc., USA et al.
2:08-cv-01658; filed April 3, 2008 in the District Court of New Jersey

Infringement of U.S. Patent No. 5,721,244 ("Combination of Angiotensin-Converting Enzyme Inhibitors with Calcium Antagonists As Well As Their Use in Drugs," issued February 24, 1998) following a paragraph IV certification as part of Glenmark’s amendment of their ANDA (adding additional dosage forms) to manufacture a generic version of plaintiffs’ Tarka® (trandolapril and verapamil hydrochloride, used to treat hypertension).  View the complaint here.